Related Experiment Video
Updated: Jul 1, 2025
12:10
Retzius-Sparing Robot-Assisted Radical Prostatectomy
Published on: May 19, 2022
7.7K
Remission Depth in Metastatic Hormone-Sensitive Prostate Cancer Is Associated With Prognosis in Patients With Initial
Takeshi Azuma1, Akimasa Katsumata1, Masato Kano1
1Urology, Tokyo Metropolitan Tama Medical Center, Tokyo, JPN.
Cureus
|March 14, 2024
Summary
Nadir prostate-specific antigen (PSA) levels can predict prognosis in metastatic hormone-sensitive prostate cancer (HSPC). This simple, accurate marker aids in assessing outcomes and guiding treatment strategies for HSPC patients.
Area of Science:
- Oncology
- Urology
- Internal Medicine
Background:
- New therapies are transforming metastatic hormone-sensitive prostate cancer (HSPC) treatment.
- Prognostic factors for metastatic HSPC are increasingly identified.
Purpose of the Study:
- To evaluate remission depth in metastatic HSPC.
- To assess the association between nadir prostate-specific antigen (PSA) and prognosis.
Main Methods:
- Analysis of 427 metastatic HSPC patients with initial PSA > 100 ng/ml.
- Nadir serum PSA as a remission depth marker, analyzed using receiver operating characteristic (ROC) curves.
- Cox proportional hazards regression to correlate nadir PSA with progression-free survival (PFS) and overall survival (OS).
Main Results:
- Cut-off values for nadir PSA were determined for time to castration resistance (TTCR) at 3, 5, 7, and 9 years.
- Nadir PSA demonstrated high sensitivity, specificity, and AUC in ROC analysis, predicting prognosis effectively.
- Nadir PSA level independently predicted TTCR and OS in multivariate analysis.
Conclusions:
- Established cut-off values for nadir PSA relative to TTCR in metastatic HSPC.
- Nadir PSA alone is a simple, accurate, and clinically useful prognostic marker for metastatic HSPC.
Keywords:
hormonal therapymetastatic hormone-sensitive prostate cancerprognosisprostate-specific antigenremission depth
